HIGHLIGHTS
- who: Mengni Bao et al. from the Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, China University of Technology, Guangzhou, China have published the Article: N-Acetylcysteine, an ROS Inhibitor, Alleviates the Pathophysiology of Hyperthyroidism-Induced Cardiomyopathy via the ROS/Ca2+ Pathway, in the Journal: Biomolecules 2022, 12, x FOR PEER REVIEW of 24/08/2022
- what: The aim of this study was to investigate the molecular mechanism of hyperthyroidism-induced cardiomyopathy (HTC) and the effect of N-acetylcysteine (NAC) an ROS inhibitor on the pathophysiology of HTC in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.